Introduction
============

Current FDA-approved deep brain stimulation (DBS) devices rely on stimulation delivered with traditional rectangular pulses including a stimulus pulse phase and a passive charge-balancing phase ([@B7]; [@B1]; [@B2]). There may, however, be opportunities to employ other stimulation strategies to tailor therapy for individual Parkinson's disease (PD) symptoms. Potential approaches may include the use of stimulation parameters with alternative pulse shaping ([@B11]; [@B7]; [@B1]) or with a modification of the pulse regularity ([@B3], [@B5]).

There has been an effort to investigate alternative approaches using computer modeling ([@B7]) and animal models ([@B12]). Human studies have unfortunately been limited to acute testing ([@B3], [@B5]). Recently, [@B1] investigated the effects of novel DBS programing pulses and strategies in a study including ambulatory PD and essential tremor (ET) patients. Square biphasic pulses (sqBIP) which utilized a stimulus pulse phase and an active, rather than a passive, charge-balancing recovery phase, were associated with improvement in blinded PD motor scores, however, patients were tested for a few minutes on each condition ([@B1]). A subsequent study by [@B2] demonstrated the safety and tolerability of biphasic pulses in ambulatory primary dystonia patients.

The literature is scant in regards to safety and tolerability of novel DBS strategies applied to movement disorders. Our study aimed to investigate safety and tolerability of sqBIP in PD patients in the outpatient setting for a 3 h-period.

Materials and Methods
=====================

The protocol was approved by the University of Florida Institutional Review Board (IRB) and registered at [ClinicalTrials.gov](https://clinicaltrials.gov) (NCT02569021). Informed consent was obtained from all participants.

Study Participants
------------------

Patients were screened during routine DBS programing sessions conducted at the University of Florida Center for Movement Disorders and Neurorestoration. The inclusion criteria were: (1) PD diagnosis made by a fellowship-trained movement disorder neurologist using the UK brain bank criteria; ([@B9]) (2) previously implanted DBS pulse generator compatible with available research software (Medtronic models Activa SC/PC/RC); (3) successful implantation of either globus pallidus interna (GPi) or subthalamic nucleus (STN) DBS with confirmation of a post-operative lead measurement to ensure adequate placement; and (4) patients stable on their DBS programing settings and medications and having attended a minimum of four monthly clinical programing optimization sessions (i.e., no need for further adjustments in medications or DBS settings based on response to changes performed during the prior month's visit). The exclusion criteria were: (1) presence of alternative neurodegenerative diagnosis other than PD; (2) previously revised DBS lead (e.g., due to infection, hardware malfunction or suboptimal placement); and (3) failure to reach the minimum required number of optimization sessions or failure to achieve optimization despite multiple programing sessions.

Study Design
------------

This was an open-label study which aimed to evaluate the safety and tolerability of sqBIP in PD. Following enrollment, patients attended a clinic visit 12 h off PD dopaminergic therapy. Patients were observed for a period of 3 h on the sqBIP setting and videotaped during serial evaluations for subsequent evaluation by raters blinded to state or time. Objective measures were obtained at condition 1 (baseline settings, ClinDBS); condition 2 (post-30 min washout with DBS off); condition 3 (30 min post-sqBIP); condition 4 (1 h post-sqBIP); condition 5 (2 h post-sqBIP); and condition 6 (3 h post-sqBIP). [Figure 1](#F1){ref-type="fig"} summarizes the study protocol and clinical conditions.
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Each subject acted as their own control, and measurements were compared across time points. Patients with unilateral DBS were converted to sqBIP, having their motor outcomes focused on that respective hemibody under the effects of stimulation. Patients with bilateral DBS had the lead contralateral to the most affected side converted to sqBIP, and the lead corresponding to the less affected side was left unchanged, on chronic home settings, to allow comparability with patients with unilateral implants.

Subjects remained under the constant supervision of a neurologist to ensure the safety and tolerability of the experimental setting. The patients were requested to report any appearance of new symptoms or any symptom changes (worsening or improvement) during the study period, which were recorded on standardized case report forms. Each symptom change was carefully classified as to the potential relationship to the DBS status.

Experimental sqBIP Settings and Outcome Measures
------------------------------------------------

A charge-balanced biphasic pulse with a square-wave active recharge was used for the study. The safety standards have been previously described ([@B1]; [@B2]). A temporary firmware update allowed modification of the charge balancing phase to be symmetric to the discharge phase. Inter-pulse intervals and stimulation parameters (i.e., amplitude, pulse width and frequency) remained unchanged. [Figure 2A](#F2){ref-type="fig"} exemplifies the changes in pulse shaping between conventional pulses and sqBIP pulses. The effects of sqBiP were assessed using the following objective measures: the part III of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score and accelerometer recordings (Kinesia Great Lakes NeuroTechnology, Cleveland, OH, United States) ([@B8]). The GAITRite walkway (GAITRite CIR systems INC., Havertown, PA, United States) was employed to objectively measure ambulation.
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Data Analysis
-------------

The SPSS version 22.0 statistical package was utilized with a pre-defined level of 0.05 for statistical significance. The categorical variables were displayed as counts and proportions, and the continuous variables were shown as medians and interquartile ranges due to the small sample size. Repeated measures were analyzed via the non-parametric Friedman's test and pairwise Wilcoxon test. Bonferroni corrections used for *post hoc* analysis when appropriate.

Results
=======

Patient Population
------------------

Nine PD patients (5 males and 4 females) were enrolled in the study, with ages ranging from 63--75 years. The disease duration ranged from 8--25 years and the time since DBS implantation ranged from 9 months to 8.5 years. Four patients had DBS leads implanted in the STN and 5 were implanted in the GPi. One patient interrupted the study at 2 h on biphasic stimulation due to difficulties tolerating the off dopaminergic medication state, and his symptoms improved after resuming his medications. [Table 1](#T1){ref-type="table"} summarizes the clinic-demographical data from the patients enrolled in the study.

###### 

Participant clinical-demographic data.

  **Subject**   **Age**   **Gender**   **Disease/DBS therapy duration**   **Unilateral vs. Bilateral DBS**   **Target tested**   **Chronic Baseline stimulation parameters**   **BIP stimulation parameters**
  ------------- --------- ------------ ---------------------------------- ---------------------------------- ------------------- --------------------------------------------- --------------------------------
  sqBIP 5       75        Female       15 years/10 months                 Unilateral                         STN                 1- C + 2.3V 90PW 135Freq                      1- C + 2.3V 90PW 130Freq
  sqBIP 6       66        Male         11 years/4 years                   Unilateral                         STN                 1- 2 + 3.8V 150PW 190Freq                     1- 2 + 3.8V 150PW 190Freq
  sqBIP 9       68        Male         20 years/11 months                 Bilateral                          Gpi                 2- C + 2.9V 90PW 135Freq                      2- C + 2.9V 90PW 130Freq
  sqBIP 10      64        Female       25 years/8 years                   Unilateral                         Gpi                 2- C + 2.2V 90PW 135Freq                      2- C + 2.2V 90PW 130Freq
  sqBIP 16      63        Female       8 years/9 months                   Unilateral                         Gpi                 2- C + 1.5V 90PW 135Freq                      2- C + 1.5V 90PW 130Freq
  sqBIP 19      66        Male         12 years/4 years                   Bilateral                          STN                 1- 2 + 3.1V 120PW 145Freq                     1- 2 + 3.1V 120PW 145Freq
  sqBIP 20      63        Male         10 years/2 years                   Bilateral                          STN                 1-3- C + 1.9V 60PW 135Freq                    1-3- C + 1.9V 60PW130Freq
  sqBIP 21      75        Male         15 years/9 years                   Bilateral                          STN                 2- C + 2.2V 90PW 135Freq                      2- C + 2.2V 90PW 130Freq
  sqBIP 22      72        Female       24 years/2 years                   Bilateral                          Gpi                 3- C + 3.1V 90PW 135Freq                      3- C + 3.1V 90PW 130Freq

Safety and Tolerability
-----------------------

All subjects tolerated the sqBiP settings without significant adverse effects throughout the 3-h period of observation. Three patients experienced non-bothersome transient paresthesias related to device reactivation, identical to when conventional clinical settings were routinely applied during their clinical care, therefore symptoms were classified as expected programing outcomes.

Motor Assessment
----------------

Blinded UPDRS motor scores were available for all nine patients. We excluded one patient from the statistical analysis since this patient inadvertently took the regular doses of levodopa throughout the day. Three of the patients experienced a slight improvement in the total UPDRS-III scores at 3 h post-sqBIP as compared to baseline DBS settings. The individual motor score data and variations across time are summarized in [Figure 2](#F2){ref-type="fig"}.

Friedman's test demonstrated statistical significance in the changes of median UPDRS motor scores values, with 26.0 (IQR = 20.5--32.5) for baseline, 34.0 (IQR = 28.0--36.5) during washout, 26.0 (IQR = 22.8--31.5), 26.0 (IQR = 19.8--28.8), 26.0 (IQR = 23.3--30.8), and 26.0 (IQR = 21.8--34.3) for 30 min, 1, 2, and 3 h post-sqBIP implementation (*p* = 0.001). Pairwise comparisons, however, demonstrated statistically significant differences only between washout and 1 h and 2 h post sqBIP, indicating potential similar effectiveness to baseline settings. A *post hoc* analysis including the patient who interrupted the study at 2 h post-sqBIP revealed similar statistical significance across the time points (*p* = 0.001).

Accelerometer data was obtained in all participants. There were no statistically significant differences between the median variables of tremor, rigidity or bradykinesia scores. Additionally, GAITRite data was available for 7 of 9 participants, and in these seven patients revealed no differences in gait speed, cadence, average step length, and average single and double support times.

Discussion
==========

This study demonstrated the safety and tolerability of using sqBIP pulses in a PD population over an acute 3-h study period. SqBIP provided a similar clinical benefit to conventional stimulation despite participants remaining in the off medication state. There were individual UPDRS motor scores which revealed non-significant improvement at 3 h post-sqBIP over time, and this failure to reach significance could have been due to the small sample size. Although the results point out lack of worsening in the sqBIP settings compared to regular stimulation and individual patient data may show some non-statistically significant improvement, the speculation of potential greater benefit cannot be supported by the current data and warrants further investigation with well-powered comparisons looking for efficacy. Noticeably, subject sqBIP 5 had no expected worsening during the washout phase. One may speculate that this participant might have needed a longer washout period than then the standard 30 min part of this study design, a phenomenon occasionally seen in clinical practice. There is a debate in the field on the determination of clinically significant washout periods and its potential impacts in study designs, which needs to be further explored in future studies. Additionally, the subject removed from the analysis for having mistakenly being on dopaminergic medications experienced an improvement from baseline, also reflected in his blinded UPDRS assessments ([Figure 2B](#F2){ref-type="fig"}), suggesting a potential benefit of the addition active recharge phase in the on state comparing to conventional DBS, which should be properly addressed in a future study. Due to the lack of appropriate power analysis and estimation of effect size aiming to evaluate clinical effectiveness, the present results are restricted to safety and tolerability outcomes.

Implementation of novel stimulation strategies has been a focus of multiple DBS research groups. Modeling studies by [@B6] have suggested that non-regular patterns of stimulation could improve effectiveness in PD, suggesting potential applicability in clinical and experimental settings. [@B4] were able to modulate tremor in an already implanted DBS patient by adding intervals between pulses, suggesting that in addition to stimulation frequencies, the timing between pulses may play a role in the effectiveness of neuromodulation strategies.

Squared biphasic pulses have been tested previously in movement disorder populations. [@B1] tested multiple novel settings in a small sample of ET and PD patients over very small time intervals (minutes). Among all the studied settings, biphasic and shorter pulses revealed significantly improved motor scores when compared to conventional stimulation, however, being associated with a higher battery consumption ([@B1]). More recently, [@B2] demonstrated the safety and tolerability of biphasic pulses in dystonia patients in a 2 h-observation study conducted in the ambulatory setting. In that study, though the sample size was small, there was a positive change in clinical response when compared to conventional DBS. Our current results are consistent with previous studies that biphasic pulses were safe and well-tolerated in movement disorders, particularly PD.

This study had several strengths as compared to previous reports. The study facilitated the testing of novel DBS programing settings by using optimized patients as their own controls and by blinding the raters to condition and time. This method reduced the possibility of several confounds that may cloud conclusions. The patients in this study were tested in the ambulatory setting for a longer observation period and this was an important procedure as the previous positive findings were reported in cases where the stimulator was only activated for a few minutes ([@B1]). However, our data is limited to unilateral DBS testing in sqBIP mode as the initial investigative step, which may not represent "real world" data where many PD patients receive bilateral DBS. Our sample size was also small and heterogeneous in regard to presence of unilateral and bilateral implantations, as well as quite variable stimulation parameters across subjects. Therefore, although study design may allow us to have some conclusions on safety and tolerability, it clearly limits our ability to draw any conclusions on effectiveness. Patients were aware of the firmware changes in settings and though the raters were blinded, this created a potential risk for a placebo response ([@B10]). The authors do believe, however, that the present study was an important step in replicating prior data over a period of hours, setting the ground for a future adequately powered study to evaluate efficacy of sqBIP in PD patients, as demonstrating efficacy will be crucial for a pulse shape which has been associated with a higher energy consumption.

Conclusion
==========

In conclusion, this study of sqBIP demonstrated its safety and tolerability over a 3-h observation period. Because sqBIP will require more energy consumption ([@B1]), leading to more neurostimulator battery changes, patients without a response to sqBIP exceeding conventional DBS will likely not be appropriate candidates for this strategy in the future. Larger, well-powered studies will be crucial to assess symptoms responsive to this approach, and will further our understanding of sqBIP in providing alternative choices for tailored programing of individual patients.
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